TAK1 inhibition for treatment of cerebral ischemia

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 68-72

  Ridder, Dirk A ^a   Schwaninger, Markus ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5Z 7 OXOZEAENOL; DUAL SPECIFICITY PHOSPHATASE 6; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B KINASE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYTAK1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMAD7 PROTEIN; SMURF1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; BRAIN ISCHEMIA; COMPLEX FORMATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; INFLAMMATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; BRAIN ISCHEMIA; MALE; MAP KINASE KINASE KINASES; ZEARALENONE;

EID: 84867801057     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.09.010     Document Type: Note

References (61)

1. Ahmed N., Zeng M., Sinha I., Polin L., Wei W.Z., Rathinam C., Flavell R., Massoumi R., Venuprasad K. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2011, 12:1176-1183.
2. Ajibade A.A., Wang Q., Cui J., Zou J., Xia X., Wang M., Tong Y., Hui W., Liu D., Su B., Wang H.Y., Wang R.F. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 2012, 36:43-54.
3. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., Legos J.J., Erhardt J.A., Ohlstein E.H., Hunter A.J., Harrison D.C., Philpott K., Smith B.R., Adams J.L., Parsons A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 2001, 21:129-145.
4. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., Weiskirchen R., Liedtke C., Gassler N., Muller M., de Vos R., Wolf M.J., Boege Y., Seleznik G.M., Zeller N., Erny D., Fuchs T., Zoller S., Cairo S., Buendia M.A., Prinz M., Akira S., Tacke F., Heikenwalder M., Trautwein C., Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappa B-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
5. Blanco S., Santos C., Lazo P.A. Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Mol. Cell. Biol. 2007, 27:7273-7283.
6. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., Bogousslavsky J., Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9:1180-1186.
7. Buglio D., Palakurthi S., Byth K., Vega F., Toader D., Saeh J., Neelapu S.S., Younes A. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood 2012, 120:347-355.
8. Cappuccio I., Calderone A., Busceti C.L., Biagioni F., Pontarelli F., Bruno V., Storto M., Terstappen G.T., Gaviraghi G., Fornai F., Battaglia G., Melchiorri D., Zukin S., Nicoletti F., Caricasole A. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J. Neurosci. 2005, 25:2647-2657.
9. Chen Z.J. Ubiquitination in signaling to and activation of IKK. Immunol. Rev. 2012, 246:95-106.
10. Cheung P.C.F., Campbell D.G., Nebreda A.R., Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38[alpha]. EMBO J. 2003, 22:5793-5805.
11. Culver C., Sundqvist A., Mudie S., Melvin A., Xirodimas D., Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol. Cell. Biol. 2010, 30:4901-4921.
12. Ellestad G.A., Lovell F.M., Perkinson N.A., Hargreaves R.T., Mcgahren W.J. New zearalenone related macrolides and isocoumarins from an unidentified fungus. J. Organomet. Chem. 1978, 43:2339-2343.
13. Herrero-Martin G., Hoyer-Hansen M., Garcia-Garcia C., Fumarola C., Farkas T., Lopez-Rivas A., Jaattela M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009, 28:677-685.
14. Herrmann O., Baumann B., De Lorenzi R., Muhammad S., Zhang W., Kleesiek J., Malfertheiner M., Köhrmann M., Potrovita I., Maegele I., Beyer C., Burke J.R., Hasan M.T., Bujard H., Wirth T., Pasparakis M., Schwaninger M. IKK mediates ischemia-induced neuronal cell death. Nat. Med. 2005, 11:1322-1329.
15. Hirt L., Badaut J., Thevenet J., Granziera C., Regli L., Maurer F., Bonny C., Bogousslavsky J. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004, 35:1738-1743.
16. Hong S., Lim S., Li A.G., Lee C., Lee Y.S., Lee E.K., Park S.H., Wang X.J., Kim S.J. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat. Immunol. 2007, 8:504-513.
17. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., Akira S., Brenner D.A., Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:844-849.
18. Inta I., Paxian S., Maegele I., Zhang W., Pizzi M., Spano P., Sarnico I., Muhammad S., Herrmann O., Inta D., Baumann B., Liou H.-C., Schmid R.M., Schwaninger M. Bim and noxa are candidates to mediate the deleterious effect of the NF-κB subunit RelA in cerebral ischemia. J. Neurosci. 2006, 26:12896-12903.
19. Irving E.A., Bamford M. Role of mitogen- and stress-activated kinases in ischemic injury. J. Cereb. Blood Flow Metab. 2002, 22:631-647.
20. Ishitani T., Ninomiya-Tsuji J., Nagai S., Nishita M., Meneghini M., Barker N., Waterman M., Bowerman B., Clevers H., Shibuya H., Matsumoto K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 1999, 399:798-802.
21. Kajino T., Ren H., Iemura S.-i, Natsume T., Stefansson B., Brautigan D.L., Matsumoto K., Ninomiya-Tsuji J. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006, 281:39891-39896.
22. Kaur S., Wang F., Venkatraman M., Arsura M. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J. Biol. Chem. 2005, 280:38599-38608.
23. Kim S.I., Kwak J.H., Wang L., Choi M.E. Protein phosphatase 2A is a negative regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial cells. J. Biol. Chem. 2008, 283:10753-10763.
24. Kim S., Kim Y., Lee J., Chung J. Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J. Biol. Chem. 2010, 285:8122-8129.
25. Kuan C.Y., Whitmarsh A.J., Yang D.D., Liao G., Schloemer A.J., Dong C., Bao J., Banasiak K.J., Haddad G.G., Flavell R.A., Davis R.J., Rakic P. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15184-15189.
26. Lackovic J., Howitt J., Callaway J.K., Silke J., Bartlett P., Tan S.S. Differential regulation of Nedd4 ubiquitin ligases and their adaptor protein Ndfip1 in a rat model of ischemic stroke. Exp. Neurol. 2012, 235:326-335.
27. Li J., Zeng Z., Viollet B., Ronnett G.V., McCullough L.D. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke 2007, 38:2992-2999.
28. Liebner S., Plate K.H. Differentiation of the brain vasculature: the answer came blowing by the Wnt. J. Angiogenes. Res. 2010, 2:1.
29. Liu H.H., Xie M., Schneider M.D., Chen Z.J. Essential role of TAK1 in thymocyte development and activation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11677-11682.
30. Lockman J.W., Reeder M.D., Robinson R., Ormonde P.A., Cimbora D.M., Williams B.L., Willardsen J.A. Oxindole derivatives as inhibitors of TAK1 kinase. Bioorg. Med. Chem. Lett. 2011, 21:1724-1727.
31. Lu X.C., Williams A.J., Yao C., Berti R., Hartings J.A., Whipple R., Vahey M.T., Polavarapu R.G., Woller K.L., Tortella F.C., Dave J.R. Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion. J. Neurosci. Res. 2004, 77:843-857.
32. Lu Q., Rau T.F., Harris V., Johnson M., Poulsen D.J., Black S.M. Increased p38 mitogen-activated protein kinase signaling is involved in the oxidative stress associated with oxygen and glucose deprivation in neonatal hippocampal slice cultures. Eur. J. Neurosci. 2011, 34:1093-1101.
33. Matsumoto-Ida M., Takimoto Y., Aoyama T., Akao M., Takeda T., Kita T. Activation of TGF-{beta}1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H709-H715.
34. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005, 280:20493-20502.
35. Melisi D., Xia Q., Paradiso G., Ling J., Moccia T., Carbone C., Budillon A., Abbruzzese J.L., Chiao P.J. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl. Cancer Inst. 2011, 103:1190-1204.
36. Momcilovic M., Hong S.-P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
37. Mortier J., Frederick R., Ganeff C., Remouchamps C., Talaga P., Pochet L., Wouters J., Piette J., Dejardin E., Masereel B. Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-kappaB activation. Biochem. Pharmacol. 2010, 79:1462-1472.
38. Murata Y., Fujiwara N., Seo J.H., Yan F., Liu X., Terasaki Y., Luo Y., Arai K., Ji X., Lo E.H. Delayed inhibition of c-Jun N-terminal kinase worsens outcomes after focal cerebral ischemia. J. Neurosci. 2012, 32:8112-8115.
39. Neubert M., Ridder D.A., Bargiotas P., Akira S., Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011, 18:1521-1530.
40. Nijboer C.H., Heijnen C.J., Groenendaal F., van Bel F., Kavelaars A. Alternate pathways preserve tumor necrosis factor-{alpha} production after nuclear factor-{kappa}B inhibition in neonatal cerebral hypoxia-ischemia. Stroke 2009, 40:3362-3368.
41. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M., Mihara M., Tsuchiya M., Matsumoto K. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 2003, 278:18485-18490.
42. Omori E., Matsumoto K., Sanjo H., Sato S., Akira S., Smart R.C., Ninomiya-Tsuji J. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 2006, 281:19610-19617.
43. Omori E., Morioka S., Matsumoto K., Ninomiya-Tsuji J. TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J. Biol. Chem. 2008, 283:26161-26168.
44. Ridder D.A., Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience 2009, 158:995-1006.
45. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., Bravata D.M., Dai S., Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus G.M., Marelli A., Matchar D.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Soliman E.Z., Sorlie P.D., Sotoodehnia N., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
46. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 2012, 33:522-530.
47. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Matsumoto K., Takeuchi O., Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005, 6:1087-1095.
48. Schneider A., Martin-Villalba A., Weih F., Vogel J., Wirth T., Schwaninger M. NF-κB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 1999, 5:554-559.
49. Schneider A., Fischer A., Kruger C., Aronowski J. Identification of regulated genes during transient cortical ischemia in mice by restriction-mediated differential display (RMDD). Brain Res. Mol. Brain Res. 2004, 124:20-28.
50. Tang M., Wei X., Guo Y., Breslin P., Zhang S., Zhang S., Wei W., Xia Z., Diaz M., Akira S., Zhang J. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 2008, 205:1611-1619.
51. Tian H.P., Qiu T.Z., Zhao J., Li L.X., Guo J. Sphingomyelinase-induced ceramide production stimulate calcium-independent JNK and PP2A activation following cerebral ischemia. Brain Inj. 2009, 23:1073-1080.
52. Wan Y.Y., Chi H., Xie M., Schneider M.D., Flavell R.A. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 2006, 7:851-858.
53. Wang Y., Bernard D.J. Activin A induction of murine and ovine follicle-stimulating hormone beta transcription is SMAD-dependent and TAK1 (MAP3K7)/p38 MAPK-independent in gonadotrope-like cells. Cell. Signal. 2012, 24:1632-1640.
54. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
55. Weng Y.C., Kriz J. Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp. Neurol. 2007, 204:433-442.
56. White B.J., Tarabishy S., Venna V.R., Manwani B., Benashski S., McCullough L.D., Li J. Protection from cerebral ischemia by inhibition of TGFbeta-activated kinase. Exp. Neurol. 2012, 237:238-245.
57. Xie M., Zhang D., Dyck J.R., Li Y., Zhang H., Morishima M., Mann D.L., Taffet G.E., Baldini A., Khoury D.S., Schneider M.D. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17378-17383.
58. Xing L., Zhang M., Chen D. Smurf control in bone cells. J. Cell. Biochem. 2010, 110:554-563.
59. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E., Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
60. Yuan Z., Becker E.B.E., Merlo P., Yamada T., DiBacco S., Konishi Y., Schaefer E.M., Bonni A. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 2008, 319:1665-1668.
61. Zhang W., Potrovita I., Tarabin V., Herrmann O., Beer V., Weih F., Schneider A., Schwaninger M. Neuronal activation of NF-κB contributes to cell death in cerebral ischemia. J. Cereb. Blood Flow Metab. 2005, 25:30-40.